Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

All products: general benefit

Other products in the same Health Canada class (D10AF) — coverage varies; not interchangeable

  • Adapalene + benzoyl peroxide + clindamycin (Cabtreo): limited Use 724
  • Clindamycin (Dalacin T 1%): not a benefit

Taro-Benzoyl Peroxide / Clindamycin Kit · DIN 02464519 · 1% & 5% · Top Gel

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Benzoyl Peroxide / Clindamycin Kit · DIN 02464519 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2017-09-28 Health Canada: Marketed since 2017-07-24 · brand TARO-BENZOYL PEROXIDE / CLINDAMYCIN KIT · ATC D10AF51 CLINDAMYCIN, COMBINATIONS · form Gel · route Topical · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1 %/W/W, BENZOYL PEROXIDE 5 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Benzoyl Peroxide / Clindamycin Kit: Formulary list price $0.7422/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7422 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95265 · Verify on the e-Formulary ↗ (DIN 02464519)

Source record
DIN 02464519: Taro-Benzoyl Peroxide / Clindamycin Kit Raw flags: sec3=Y Item: 840404029; group id 811; item number 1990; lccId None; manufacturer id TAR Source form: Top Gel; strength: 1% & 5% Recorded listing: General benefit Source prices (unrounded): $0.7422; ministry $0.7422 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464519 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95265
Interchangeable products
BenzaClin Topical Gel · DIN 02248472 · $0.7422
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE Some products covered without a code (check the product listing): MUPIROCIN 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE BENZACLIN (clindamycin, as phosphate, 1% and benzoyl peroxide 5%) is indicated for:  The topical treatment of moderate acne vulgaris characterized by comedones, inflammatory papules/pustules, with or without an occasional cyst or nodule (Grade II to III 1). BENZACLIN contains an antibacterial ingredient, clindamycin. To reduce the risk of development of drug-resistant bacteria and maintain the effectiveness of clindamycin, BENZACLIN should only be used for the authorized indication and clinical use. BENZACLIN is not indicated for the treatment of cystic acne (Grade IV 1). https://pdf.hres.ca/dpd_pm/00060577.PDF PM date: March 29, 2021 Source product: BENZACLIN; DIN 02248472; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.